Latest Articles

Publication Date
When It's Not Just "That Time of the Month": Identifying Thoracic Endometriosis in the Context of Recurrent Pleural Effusion.

Recurrent hemorrhagic pleural effusion presents as a challenge for both the clinician and the patient, with common causes being tuberculosis, malignancy, and collagen vascular diseases. Among uncommon causes of recurrent …

Published: Aug. 4, 2026, midnight
A Mouse Model of Endometriosis Using Ex Vivo Cy5.5 Dye-Doped Silica Nanoparticle Labeling for Lesion Visualization.

Endometriosis is a common gynecological disorder characterized by the growth of endometrial-like tissue outside the uterine cavity, leading to chronic inflammation, pelvic pain, and infertility. Reliable mouse models are essential …

Published: Aug. 4, 2026, midnight
Dietary and Environmental Exposure to Toxic Elements in Endometriosis: A Missing Piece of the Etiological Puzzle?

Background/Objectives: Endometriosis is a chronic estrogen-dependent disease with a complex and incompletely understood etiology. Environmental exposure to toxic elements, including cadmium, lead, mercury, and arsenic, may contribute to its development …

Published: Aug. 2, 2026, midnight
Superficial Peritoneal Endometriosis Beyond Surgical Diagnosis: A Narrative Review of Emerging Functional and Molecular Perspectives.

Background and Objectives: Superficial peritoneal endometriosis (SPE) remains one of the most difficult endometriosis phenotypes to diagnose non-invasively, because lesions are frequently small, multifocal, and poorly detectable using conventional imaging. …

Published: Aug. 2, 2026, midnight
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com - Investing.com UK

H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com Investing.com UK

Published: Aug. 1, 2026, 6:38 a.m.
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard

Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial The Clinical Trial Vanguard

Published: Aug. 1, 2026, 6:33 a.m.
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted Oncology

Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer Targeted Oncology

Published: July 31, 2026, 8:06 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLive

Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer OncLive

Published: July 31, 2026, 5:22 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - onclive.com

Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer onclive.com

Published: July 31, 2026, 5:22 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetwork

Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer CancerNetwork

Published: July 31, 2026, 2:37 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!